What's happening
This bill requires insurance policies in New York to cover testing for familial dysautonomia, Canavan's disease, and Tay-Sachs.
Why it matters
Expands access to genetic testing for serious inherited diseases. by requiring insurance coverage for familial dysautonomia, Canavan's disease, and Tay-Sachs, potentially leading to earlier detection and intervention for at-risk individuals or families.
Ensures inclusion in all types of insurance policies. individual, group, and health service plans—meaning that a broad spectrum of New Yorkers, regardless of how they are insured, would benefit from this mandate.
Addresses privacy concerns. by allowing proof of testing through a simple laboratory acknowledgment, which helps protect the confidentiality of individuals undergoing genetic testing.
Keeps coverage in line with existing policy structures. by allowing insurers to apply deductibles and coinsurance similar to other medical benefits, aiming to balance expanded access with manageable insurance costs and administration.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Cover Genetic Disease Testing
Plain English, a few words. Used as the page title.
Sponsors
History
- Referred to insurance
- Referred to insurance
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Cover Genetic Disease Testing
In Senate Committee · Insurance · Sponsor Anna Kaplan
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
2272
2021-2022 Regular Sessions
IN ASSEMBLY
January 14, 2021
Introduced by M. of A. DINOWITZ -- read once and referred to the Committee on Insurance
AN ACT to amend the insurance law, in relation to reimbursement for testing for familial dysautonomia, Canavan's disease and Tay-Sachs
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subsection (i) of section 3216 of the insurance law is amended by adding a new paragraph 36 to read as follows:
(36) (A) Every policy which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or reimbursement for diagnostic X-ray services shall provide coverage for testing for familial dysautonomia, Canavan's disease and Tay-Sachs.
(B) Such coverage shall be included at the inception of all new policies and, with respect to all other policies, at any anniversary date of the policy subject to evidence of insurability.
(C) For purposes of this paragraph, in order to maintain the confidentiality of persons tested, receipt of an acknowledgment from the laboratory performing the test for familial dysautonomia, Canavan's disease and Tay-Sachs shall be deemed sufficient evidence of the performance of such testing.
(D) Such coverage may be subject to annual deductibles and co-insurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy.
§ 2. Subsection (l) of section 3221 of the insurance law is amended by adding a new paragraph 21 to read as follows:
(21) (A) A group policy which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or reimbursement for diagnostic X-ray services shall provide coverage for testing for familial dysautonomia, Canavan's disease and Tay-Sachs.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD05333-01-1
A. 2272 2
(B) Such coverage shall be included at the inception of all new policies and, with respect to all other policies, at any anniversary date of the policy subject to evidence of insurability.
(C) For purposes of this paragraph, in order to maintain the confidentiality of persons tested, receipt of an acknowledgment from the laboratory performing the test for familial dysautonomia, Canavan's disease and Tay-Sachs shall be deemed sufficient evidence of the performance of such testing.
(D) Such coverage may be subject to annual deductibles and co-insurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy.
§ 3. Section 4303 of the insurance law is amended by adding a new subsection (ss) to read as follows:
(ss) (1) A medical expense indemnity corporation, a hospital service corporation or a health service corporation which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or reimbursement for diagnostic X-ray services shall provide coverage for testing for familial dysautonomia, Canavan's disease and Tay-Sachs.
(2) Such coverage shall be included at the inception of all new policies and, with respect to all other policies, at any anniversary date of the policy subject to evidence of insurability.
(3) For purposes of this subsection, in order to maintain the confidentiality of persons tested, receipt of an acknowledgment from the laboratory performing the test for familial dysautonomia, Canavan's disease and Tay-Sachs shall be deemed sufficient evidence of the performance of such testing.
(4) Such coverage may be subject to annual deductibles and co-insurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy.
§ 4. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.